about
The thioxotriazole copper(II) complex A0 induces endoplasmic reticulum stress and paraptotic death in human cancer cellsA molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.Exploiting orthologue diversity for systematic detection of gain-of-function phenotypes.The GAB2 signaling scaffold promotes anchorage independence and drives a transcriptional response associated with metastatic progression of breast cancer.Mulcom: a multiple comparison statistical test for microarray data in BioconductorEfficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer.Knock-in of oncogenic Kras does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers.Transcriptional hallmarks of Noonan syndrome and Noonan-like syndrome with loose anagen hair.High-throughput molecular analysis from leftover of fine needle aspiration cytology of mammographically detected breast cancer.The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis.MicroRNA-mRNA interactions underlying colorectal cancer molecular subtypes.Primary breast cancer stem-like cells metastasise to bone, switch phenotype and acquire a bone tropism signature.The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.Stromal contribution to the colorectal cancer transcriptome.TNF-α promotes invasive growth through the MET signaling pathway.A molecular signature for Epithelial to Mesenchymal transition in a human colon cancer cell system is revealed by large-scale microarray analysis.Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer.IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies.The miR-126 regulates angiopoietin-1 signaling and vessel maturation by targeting p85β.Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsies.A Molecularly Annotated Model of Patient-Derived Colon Cancer Stem-Like Cells to Assess Genetic and Nongenetic Mechanisms of Resistance to Anti-EGFR Therapy.MACC1 mRNA levels predict cancer recurrence after resection of colorectal cancer liver metastases.Rituximab Treatment Prevents Lymphoma Onset in Gastric Cancer Patient-Derived Xenografts.The unfolded protein response: a novel therapeutic target for poor prognostic BRAF mutant colorectal cancer.MiR-1 downregulation cooperates with MACC1 in promoting MET overexpression in human colon cancer.FOXA1 and AR in invasive breast cancer: new findings on their co-expression and impact on prognosis in ER-positive patients.Genetic and Expression Analysis of MET, MACC1, and HGF in Metastatic Colorectal Cancer: Response to Met Inhibition in Patient Xenografts and Pathologic CorrelationsIntegration of transcriptomic data and metabolic networks in cancer samples reveals highly significant prognostic powerHigh USP6NL Levels in Breast Cancer Sustain Chronic AKT Phosphorylation and GLUT1 Stability Fueling Aerobic GlycolysisNeuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapiesA Comprehensive PDX Gastric Cancer Collection Captures Cancer Cell-Intrinsic Transcriptional MSI TraitsIncreased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted TherapiesA Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and OxaliplatinPatient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal CancerReverse signaling by semaphorin 4C elicits SMAD1/5- and ID1/3-dependent invasive reprogramming in cancer cellsA Genomic Analysis Workflow for Colorectal Cancer Precision OncologyEvolving neoantigen profiles in colorectal cancers with DNA repair defects
P50
Q24651419-29188D87-C252-4A3E-B753-58ECE7A38E74Q27851787-84B611C3-C89C-470C-BAC1-3DF6D99737EAQ33338660-F3DA40B6-2646-487F-83CD-22F138C1B80BQ33511204-108E1FE8-0717-41C5-96A1-3B866E1768FAQ34034125-00A75E40-3736-4F3D-803E-0DE8CBA30D91Q34543264-08371740-E68A-4F45-A064-97A951A9ED2CQ34688930-738DFBEF-B64B-4CDC-889B-287BE4D2089CQ35903618-065BD471-2E03-44AE-BEF8-6CE0388B19A3Q36061792-B230307A-4AC4-437C-B483-E06BC54537A2Q36090214-8D60DE86-2BBC-4B16-9D03-4B79A0BEE0C8Q36320483-B3746B5B-2520-4BE9-9E2F-67ACC14B2E87Q36959186-F446EA30-5972-4711-8261-639F5B3CFD90Q38880745-A79C7FDD-E209-4790-818E-7B8301DD5024Q38906913-CB01C1D6-1BC7-49CD-90D3-C5A8C57DD85DQ38948786-04F8156F-8F1B-41BF-B29B-281224C9E58CQ39865031-3ED1A7A7-0069-4A2A-8AD8-6A8258ED58A7Q40953655-96C6A8FE-F440-46D2-957C-84D8315C29D4Q41511106-BFA3E8DE-F2EB-4BF1-9977-AFED7B59E6C6Q44464268-8F72ED06-B6EE-470B-831D-C006BD748E44Q48089525-C5E0766E-7411-49E4-AD25-98C59F2FA2A2Q49643002-0CE52A0D-525B-4791-9E17-8B8C91EEA393Q51000683-46AE6264-D172-4335-8990-073D0B3575A1Q52638232-0D475ADE-CD70-4231-8D64-50EA43BE9AF3Q52684450-879B7F35-1200-4211-9B96-2C77D92F49C6Q54333498-8D942735-DC97-4100-A845-2809B05E82E8Q55517966-C5B064E3-F7C1-4512-929C-2CB174E4134EQ56688160-71E4BDCC-F180-494B-9E95-011D40D8310BQ62678513-2FC7B30A-902F-4918-B8A1-5C33BD193C99Q88461744-68EFC9DD-16E6-4F6A-BF51-E00FAFFAE30BQ89312213-9F2DFE71-188D-4AFA-ADDC-D8C60DC98ED2Q90493756-001BEFE6-8AF1-4448-B83B-BFF0F24DAF2CQ91264742-7158492A-A0F2-413F-9A03-870579784E4FQ91930559-42B48323-0FB1-4C95-9CAA-0AADBE45BADEQ92376032-1E3A063E-FA62-49ED-AE55-FB7B894787B5Q92734518-88CCC1E9-02D6-4898-815B-6A327C5F81A7Q93074969-1E9ACE31-B125-4365-88C8-1CCE81B12DB9Q93111962-2EFD3851-ED70-4EA4-B09E-9501436DF760
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Claudio Isella
@ast
Claudio Isella
@en
Claudio Isella
@es
Claudio Isella
@nl
type
label
Claudio Isella
@ast
Claudio Isella
@en
Claudio Isella
@es
Claudio Isella
@nl
prefLabel
Claudio Isella
@ast
Claudio Isella
@en
Claudio Isella
@es
Claudio Isella
@nl
P106
P1153
24436087400
P21
P31
P496
0000-0003-0679-4756